Literature DB >> 2616107

Effect of Lugol's iodine on the vascularity of thyroid gland in hyperthyroidism.

M Rangaswamy1, A K Padhy, P G Gopinath, N K Shukla, K Gupta, M M Kapoor.   

Abstract

Vascularity of the thyroid gland was measured in twenty thyrotoxic patients (including Graves and multinodular goitres) and eight normal subjects by a new objective parameter--'Thyroid Vascularity Index' (TVI). The TVI was calculated by comparing the areas under the normalized thyroid and carotid artery curves up to the time of peak of the arterial curve caused by the first passage of a radioactive bolus. Compared to normal thyroid, all the toxic goitres had increased TVI (p less than 0.001); it being maximum in Graves disease (p less than 0.05). TVI in Graves disease was not affected by carbimazole therapy but decreased dramatically in eight out of ten patients (p less than 0.01) two weeks after Lugol's iodine was added. There was a sustained fall in TVI in all the ten patients (p less than 0.001) with chronic iodine therapy up to six weeks without any hormonal escape. TVI in multinodular goitres showed no significance change with carbimazole or iodine therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2616107     DOI: 10.1097/00006231-198909000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  2 in total

1.  Excess iodide decreases transcription of NIS and VEGF genes in rat FRTL-5 thyroid cells.

Authors:  Koichi Suzuki; Hiroaki Kimura; Huhehasi Wu; Naoko Kudo; Won Bae Kim; Sayuri Suzuki; Akio Yoshida; Patrizio Caturegli; Leonard D Kohn
Journal:  Biochem Biophys Res Commun       Date:  2010-02-02       Impact factor: 3.575

2.  Is rapid preparation for thyroidectomy in severe Graves' disease beneficial? The relationship between clinical and immunohistochemical aspects.

Authors:  Iyad Hassan; Radu Danila; Heisam Aljabri; Sebastian Hoffmann; Annette Wunderlich; Elias Karakas; Andreas Zielke
Journal:  Endocrine       Date:  2008-05-21       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.